SCHEMBL19006328

SCHEMBL19006328

CC(C)NC(=N)c1ccc(N=O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.41
KMT2A Q03164 4/20 0.41
CYP2C9 P11712 2/20 0.41
HSD17B10 Q99714 3/20 0.39
PKM P14618 1/20 0.36
CASP3 P42574 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
TSHR P16473 2/20 0.35
TP53 P04637 1/20 0.35
MAPK1 P28482 1/20 0.35
HIF1A Q16665 1/20 0.35
MLYCD O95822 1/20 0.35
TDP1 Q9NUW8 2/20 0.33
CYP3A4 P08684 1/20 0.33
HTT P42858 1/20 0.33
KDM4E B2RXH2 1/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C19 P33261 2/20 0.33
LMNA P02545 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2760492 0.76 ALDH1A1 (0.50) ALDH1A1KMT2ACYP2C9HSD17B10PKM
SCHEMBL18735681 0.76 MEN1 (0.41) ALDH1A1KMT2APKMTDP1HTT
SCHEMBL23718011 0.75 ALDH1A1 (0.42) ALDH1A1KMT2AMLYCDHTTCYP1A2
SCHEMBL17469782 0.75 PLAU (0.46) ALDH1A1KMT2AHSD17B10PKMTSHR
SCHEMBL27396355 0.75 ALDH1A1 (0.50) ALDH1A1KMT2ATSHRMAPK1CYP3A4
SCHEMBL17826836 0.75 CYP1A2 (0.37) ALDH1A1MLYCDCYP1A2CYP2C19LMNA
SCHEMBL15614990 0.74 PKM (0.41) ALDH1A1KMT2ACYP2C9HSD17B10PKM
Hydrochloric Acid SCHEMBL28547551 0.72 BLM (0.43) ALDH1A1KMT2ACYP2C9HSD17B10PKM
SCHEMBL17469781 0.71 MAPK1 (0.50) ALDH1A1KMT2ATSHRTP53MAPK1
SCHEMBL8861374 0.71 MLYCD (0.31) MLYCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170174620-A1 LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME UNIVERSITY OF MARYLAND, COLLEGE PARK 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174620-A1 LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME MCL1, DPYD, TOP2B ALDH1A1 635/4885KMT2A 1271/4885CYP2C9 1826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.